Presentation is loading. Please wait.

Presentation is loading. Please wait.

N. la Cour Freiesleben, T. A. Gerds, J. L. Forman, J. D. Silver, A

Similar presentations


Presentation on theme: "N. la Cour Freiesleben, T. A. Gerds, J. L. Forman, J. D. Silver, A"— Presentation transcript:

1 Risk charts to identify low and excessive responders among first-cycle IVF/ICSI standard patients 
N. la Cour Freiesleben, T.A. Gerds, J.L. Forman, J.D. Silver, A. Nyboe Andersen, B. Popovic-Todorovic  Reproductive BioMedicine Online  Volume 22, Issue 1, Pages (January 2011) DOI: /j.rbmo Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions

2 Figure 1 Risk charts for identification of standard IVF/ICSI patients’ risks of low and excessive ovarian responses in the first treatment cycle. Based on the total antral follicle count (AFC) (2–10mm) and the female age (years), a patient’s estimated risk (%) of low response (seven or less follicles) is identified from the top chart. Based on the total AFC and the spontaneous cycle length (days), a patient’s estimated risk (%) of excessive response (20 or more follicles) is identified from the bottom chart. The identified risks correspond to a starting dose of 150IU rFSH/day. Reproductive BioMedicine Online  , 50-58DOI: ( /j.rbmo ) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions

3 Figure 2 Example of how risk estimates of low and excessive ovarian responses to a dose of 150IU rFSH/day (Figure 1) may be used for individual rFSH dosing in standard patients’ first IVF/ICSI treatment cycle. Along the diagonal where the predicted risk of low response is equal to the risk of excessive response, the dose is 150IU. The dose increases with increasing risk of low response and with decreasing risk of excessive response. Conversely, the dose decreases with increasing risk of excessive response and with decreasing risk of low response. The circles represent the predicted risks for each patient. Clinicians (and patients) may indeed have their own preferences regarding risks versus a reasonable dose in each individual case. Reproductive BioMedicine Online  , 50-58DOI: ( /j.rbmo ) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions


Download ppt "N. la Cour Freiesleben, T. A. Gerds, J. L. Forman, J. D. Silver, A"

Similar presentations


Ads by Google